Cytori Therapeutics Inc (CYTX) Major Shareholder Sells $80,292.70 in Stock

Cytori Therapeutics Inc (NASDAQ:CYTX) major shareholder Ag Postfinance sold 236,155 shares of the business’s stock in a transaction that occurred on Friday, February 9th. The shares were sold at an average price of $0.34, for a total value of $80,292.70. Following the completion of the transaction, the insider now directly owns 5,311,451 shares of the company’s stock, valued at $1,805,893.34. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Large shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Cytori Therapeutics Inc (CYTX) traded down $0.01 during trading on Monday, hitting $0.31. The stock had a trading volume of 556,715 shares, compared to its average volume of 2,460,000. The stock has a market capitalization of $10.89, a PE ratio of -0.34 and a beta of 3.56. Cytori Therapeutics Inc has a 1-year low of $0.22 and a 1-year high of $2.13.

Cytori Therapeutics (NASDAQ:CYTX) last posted its quarterly earnings data on Thursday, November 9th. The biotechnology company reported ($0.14) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.16) by $0.02. The business had revenue of $1.77 million during the quarter, compared to analysts’ expectations of $2.04 million. Cytori Therapeutics had a negative return on equity of 228.21% and a negative net margin of 367.33%. During the same period in the previous year, the business earned ($0.26) earnings per share. equities analysts predict that Cytori Therapeutics Inc will post -0.62 earnings per share for the current fiscal year.

A number of research firms have recently commented on CYTX. Maxim Group set a $5.00 price objective on Cytori Therapeutics and gave the company a “buy” rating in a research report on Thursday, October 19th. Zacks Investment Research cut Cytori Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, November 9th. ValuEngine upgraded Cytori Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Friday, February 2nd. Finally, B. Riley restated a “hold” rating on shares of Cytori Therapeutics in a research report on Tuesday, November 7th.

Institutional investors have recently bought and sold shares of the company. Perkins Capital Management Inc. increased its position in shares of Cytori Therapeutics by 134.0% in the fourth quarter. Perkins Capital Management Inc. now owns 2,136,041 shares of the biotechnology company’s stock valued at $644,000 after buying an additional 1,223,046 shares in the last quarter. Vanguard Group Inc. increased its position in shares of Cytori Therapeutics by 81.9% in the second quarter. Vanguard Group Inc. now owns 612,304 shares of the biotechnology company’s stock valued at $674,000 after buying an additional 275,653 shares in the last quarter. Finally, Sabby Management LLC increased its position in shares of Cytori Therapeutics by 28.0% in the second quarter. Sabby Management LLC now owns 1,626,807 shares of the biotechnology company’s stock valued at $1,789,000 after buying an additional 355,504 shares in the last quarter. Institutional investors and hedge funds own 10.82% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Cytori Therapeutics Inc (CYTX) Major Shareholder Sells $80,292.70 in Stock” was originally reported by American Banking News and is owned by of American Banking News. If you are viewing this piece of content on another domain, it was illegally copied and republished in violation of U.S. & international copyright and trademark legislation. The legal version of this piece of content can be accessed at https://www.americanbankingnews.com/2018/02/12/cytori-therapeutics-inc-cytx-major-shareholder-sells-80292-70-in-stock.html.

Cytori Therapeutics Company Profile

Cytori Therapeutics, Inc (Cytori) is a biotechnology company engaged in the development of treatments and devices for a range of disorders using cells as a key part of the therapy. The Company develops cellular therapeutics formulated and optimized for specific diseases and medical conditions and related products.

Receive News & Ratings for Cytori Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytori Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply